Employing Biomarker Based ADC Translational Studies to Identify Patients Most Sensitive to ADC Performance - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Employing Biomarker Based ADC Translational Studies to Identify Patients Most Sensitive to ADC Performance

2:00 pm - Tuesday 13th October 2026

Prioritizing biomarker and patient selection approaches to reflect a maturing ADC clinical development pipeline
Highlighting biomarker development to identify patients with the most sensitive ADC response
Utilizing reverse translation approaches to understand mechanisms behind clinical success to apply to ongoing ADC translational studies

Speakers:

Jack Chen

Jack Chen

Director - Scientific Translational Oncology, Precision Medicine

Abbvie